Biocon Limited has entered into a global patent settlement and licence agreement with Genentech, a subsidiary of Roche, resolving pending disputes over Pebrilzo, its biosimilar to Perjeta (pertuzumab), a biologic medicine used to treat HER2-positive breast cancer. The agreement establishes launch timelines for the drug
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), today announced that Siddharth Mittal has assumed the role of Managing Director and Chief Executive Officer of the Company, effective 1 July 2026. Siddharth succeeds Peter Bains, who completed his tenure as Managing Director &
Join 2M+ industry professionals with MedgateToday - curated insights, delivered daily.
